# Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

> **NCT02405013** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 120 (actual)

## Conditions studied

- Hepatitis C
- HIV Infection

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin
- **DRUG:** Sofosbuvir
- **DRUG:** Ledipasvir

## Key facts

- **NCT ID:** NCT02405013
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-07
- **Final completion:** 2017-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405013, "Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02405013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*